Closing Remarks on Bispecific Antibodies

Justin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.

EP: 1.Introduction to Bispecific Antibodies: Operationalizing Administration and Follow-Up

EP: 2.Overview of Bispecific Engagers Administration Program

EP: 3.Program Development and SOPs for Bispecific Engagers

EP: 4.Treating Patients With Bispecific Engagers

EP: 5.The Grading and Management of Early and Late Adverse Events

EP: 6.How Administration of Bispecific T-Cell Engagers Has Evolved

Now Viewing

EP: 7.Closing Remarks on Bispecific Antibodies

Related Videos